Esperion Therapeutics, Inc.
(NASDAQ : ESPR)

( )
ESPR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.55%73.740.9%$598.99m
CELGCelgene Corporation
-0.84%129.191.1%$425.21m
AMGNAmgen Inc.
-0.63%169.001.1%$397.19m
BIIBBiogen Inc.
-1.42%282.641.2%$346.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%477.152.7%$319.17m
VRTXVertex Pharmaceuticals Incorporated
-1.43%153.251.9%$227.49m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%135.671.9%$211.59m
ILMNIllumina, Inc.
-0.59%193.623.5%$208.34m
KITEKite Pharma, Inc.
1.63%138.1716.1%$135.10m
INCYIncyte Corporation
-0.17%123.652.6%$130.04m
CLVSClovis Oncology, Inc.
-0.68%71.6118.0%$125.25m
TSROTESARO, Inc.
-0.18%120.4014.7%$124.85m
AAgilent Technologies, Inc.
-0.30%62.771.5%$122.45m
BMRNBioMarin Pharmaceutical Inc.
-0.07%81.404.4%$105.16m
SRPTSarepta Therapeutics, Inc.
-2.38%36.0719.8%$88.80m

Company Profile

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. Esperion Therapeutics was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.